Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Dose Titration Study of ANAVEX2-73 in Patients With Rett Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2023
Price :
$35
*
At a glance
- Drugs Blarcamesine (Primary)
- Indications Rett syndrome
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- Acronyms U.S. RTT
- Sponsors Anavex Life Sciences
- 28 Jun 2023 According to an Anavex Life Sciences media release, Anavex plans to submit the data for publication in a peer-reviewed medical journal.
- 28 Jun 2023 Results published in the Anavex Life Sciences Media Release
- 21 Jun 2021 Results published in an Anavex Life Sciences Media Release.